Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392856 | 0.86 | ALDH1A1 (0.52) | HSD17B10USP2TDP1HTTMEN1 | |
| SCHEMBL17278043 | 0.81 | USP2 (0.55) | HSD17B10USP2HTTMEN1KMT2A | |
| SCHEMBL27953890 | 0.81 | USP2 (0.67) | HSD17B10USP2TDP1HTTMEN1 | |
| SCHEMBL12752105 | 0.81 | MEN1 (0.33) | HSD17B10USP2MEN1KMT2A | |
| SCHEMBL20927199 | 0.79 | HSD17B10 (0.54) | HSD17B10USP2TDP1HTTMEN1 | |
| SCHEMBL22219040 | 0.79 | ALDH1A1 (0.39) | HSD17B10USP2HTTMEN1KMT2A | |
| SCHEMBL21046022 | 0.77 | USP2 (0.68) | USP2HTTMEN1KMT2ATHRB | |
| SCHEMBL21046018 | 0.77 | USP2 (0.68) | USP2HTTMEN1KMT2ATHRB | |
| SCHEMBL21046040 | 0.77 | USP2 (0.68) | USP2HTTMEN1KMT2ATHRB | |
| SCHEMBL16367888 | 0.77 | USP2 (0.68) | USP2HTTMEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546616-B2 | Polyetheramine macromonomers comprising two neighboring hydroxyl groups and their use for producing polyurethanes | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-10-01 | — | — | US | disclosed |
| US-20090318656-A1 | Polyetheramine Macromonomers Comprising Two Neighboring Hydroxyl Groups And Their Use For Producing Polyurethanes | CLARIANT INTERNATIONAL LTD. (CH) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318656-A1 | Polyetheramine Macromonomers Comprising Two Neighboring Hydroxyl Groups And Their Use For Producing Polyurethanes | PNMT, BHMT2, PUF60 | HSD17B10 1190/4885USP2 483/4885TDP1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.